Who
Brian M. Strem
President and CEO
Company insider
Files Form 4 as: President and CEO, Kiora Pharmaceuticals.
In numbers
- Trades disclosed
- 25
- Buys
- 2
- Sells
- 0
- Bought
- $40K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Jul 2021
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $4,9721,869 at $2.66 | filing |
| 1 Jul 2026filed 2 Jul 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $4,9721,869 at $2.66 | filing |
| 1 Apr 2026filed 2 Apr 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $3,7171,906 at $1.95 | filing |
| 1 Apr 2026filed 2 Apr 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $3,7171,906 at $1.95 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,733 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,467 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,467 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,733 at $0.00 | filing |
| 3 Mar 2026filed 6 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $481238 at $2.02 | filing |
| 3 Mar 2026filed 6 Mar 2026 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $481238 at $2.02 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,883 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,941 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,259 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,629 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $15K3,000 at $5.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,400 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $60K15,600 at $3.83 | filing |
| 21 Oct 2022filed 25 Oct 2022 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
News
Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveyKPRX · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Brian M. Strem; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.